Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FPRX

Five Prime Therapeutics (FPRX) Stock Price, News & Analysis

Five Prime Therapeutics logo

About Five Prime Therapeutics Stock (NASDAQ:FPRX)

Advanced Chart

Key Stats

Today's Range
$38.00
$38.00
50-Day Range
$37.65
$38.00
52-Week Range
$2.61
$38.90
Volume
N/A
Average Volume
1.98 million shs
Market Capitalization
$1.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive FPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Five Prime Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

FPRX Stock News Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.tc pixel
CMMB Chemomab Therapeutics Ltd.
What Is The Prime Rate Today?
See More Headlines

FPRX Stock Analysis - Frequently Asked Questions

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) released its quarterly earnings results on Friday, November, 6th. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by $0.14. The biotechnology company had revenue of $2.05 million for the quarter, compared to the consensus estimate of $3.50 million. Five Prime Therapeutics had a negative net margin of 554.71% and a negative trailing twelve-month return on equity of 75.84%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Five Prime Therapeutics investors own include Bristol Myers Squibb (BMY), Gilead Sciences (GILD), OPKO Health (OPK), Pfizer (PFE), Nektar Therapeutics (NKTR), Advanced Micro Devices (AMD) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
11/06/2020
Today
8/29/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FPRX
CIK
1175505
Fax
N/A
Employees
87
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.92)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$137.20 million
Net Margins
-554.71%
Pretax Margin
N/A
Return on Equity
-75.84%
Return on Assets
-49.08%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.35
Quick Ratio
5.35

Sales & Book Value

Annual Sales
$14.87 million
Price / Sales
119.01
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.13 per share
Price / Book
9.20

Miscellaneous

Outstanding Shares
46,572,000
Free Float
N/A
Market Cap
$1.77 billion
Optionable
Optionable
Beta
4.40
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:FPRX) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners